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Here we report c-Abl kinase inhibition mediated by a phosphotyrosine located in trans in the c-Abl substrate, Abi1. The mechanism, which is
pertinent to the nonmyristoylated c-Abl kinase, involves high affinity concurrent binding of the phosphotyrosine pY213 to the Abl SH2 domain
and binding of a proximal PXXP motif to the Abl SH3 domain. Abi1 regulation of c-Abl in vivo appears to play a critical role, as demonstrated by
inhibition of pY412 phosphorylation of the nonmyristoylated Abl by coexpression of Abi1. Pervanadate-induced c-Abl kinase activity was also
reduced upon expression of the wild type Abi1 but not by expression of the Y213 to F213 mutant Abi1 in LNCaP cells, which are naturally
deficient in the regulatory pY213. Our findings suggest a novel mechanism by which Abl kinase is regulated in cells.
© 2008 Elsevier B.V. All rights reserved.Keywords: c-Abl; Tyrosine kinase activity; Abi1; Hssh3bp1; Allosteric mechanism; SH3 and SH2 domain1. Introduction
The ubiquitous nonreceptor tyrosine kinase, c-Abl kinase,
plays an essential role in cell signal transduction, balancing
events leading to apoptosis or to increased cell proliferation
[1,2]. The critical role of c-Abl kinase in cell proliferation is
illustrated by the dramatic manifestation of chronic myelogen-
ous leukemia (CML) due to expression of BCR-Abl, a kinase-
activated mutant form of c-Abl tyrosine kinase [3,4]. Rational
approaches to curtail BCR-Abl kinase activity led to the devel-
opment of STI-571 (imanitib mesylate, or Gleevec) [5] as the
successful treatment of CML [6]. However, the appearance of
Gleevec-resistance mutations [7,8], that becomes an issue in
advanced stage CML [9] led to re-thinking of the mechanism of
BCR-Abl regulation. This has brought attention back to c-Abl,
since BCR-Abl and c-Abl share most regulatory domains [2,10].⁎ Corresponding author. Laboratory of Cell Signaling, 310 E 67th St., New
York, NY 10065, USA. Tel.: +1 212 570 3228; fax: +1 212 570 3355.
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c-Src and c-Abl [11,12]. These kinases share high structural
homology conferred by the presence of highly conserved
structural domains: SH3, SH2, and the catalytic domain. Crystal
structures of c-Src [13,14] and c-Abl [15,16] revealed that SH3
and SH2 domains bind to the catalytic domain (CD) inducing an
autoinhibitory conformation,which provides the basicmechanism
of regulation of these kinases. This basic regulation is preserved in
BCR-Abl, which retains the c-Abl SH2 and SH3 domains.
c-Src and c-Abl differ from each other in two mechanisms
that inhibit activities of these kinases. In c-Src, inhibition is
achieved by intramolecular interaction of the SH2 domain with
the phosphorylated tyrosine 527 located in the C-terminal region
of the same molecule [17]. In c-Abl there is no internal
phosphotyrosine-SH2 domain interaction, precluding this inhi-
bitorymechanism. Additional inhibitory constraints are imposed
on c-Abl both by the myristoylated cap which binds directly to
the C-terminal lobe of the kinase domain, and by the cap region
phosphoserine 69 which binds to the SH2 domain [18]. These
interactions further serve to lock the SH3-SH2 “clamp” onto the
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pounds mimicking its action [19], stabilize the position of the
C-terminal helix of the catalytic domain, αI, resulting in the
inhibited conformation of the kinase. The “molecular lock”
imposed by the myristoylated cap, however, does not exist in the
nonmyristoylated form of c-Abl, isoform 1a, which contains
only a partial cap region, or in BCR-Abl, in which the cap region
is replaced by BCR. Thus, the kinase activities of BCR-Abl, and
c-Abl-1a, are not regulated by themyristoylated cap although the
phosphoserine 69 is preserved in c-Abl-1a, where it may
contribute to the autoinhibitory mechanism [18]. Intramolecular
interactions of the cap regionmay also regulate accessibility, and
therefore, may regulate binding of Abl SH3 or SH2 ligands
including phosphotyrosine-containing peptides from growth
factors, which may play a role in the myristoylated c-Abl kinase
activation [15]. Considering the complexity of Abl regulation,
activation of the kinase activity is likely to involvemultiple steps
leading to uncoupling of SH3 and SH2 domains from the
catalytic domain thereby “freeing” the kinase from inhibition.
Although not yet demonstrated with Abi proteins, peptides that
combine both Abl SH3 and SH2 binding sites into a single
consolidated ligand show enhanced binding affinities for the
dual SH3–SH2 domain, pointing to the possibility that these
domains may act as one functional unit in c-Abl [20].
Various proteins, including Abi1 and Abi2, that bind to c-Abl
kinase have been proposed to be c-Abl co-inhibitors [12,21,22].
Abi1 and Abi2 have been thought to play a role in the regulation
of cell growth [21–23] but the molecular mechanism is not clear.
Abi1 and Abi2 were proposed to regulate c-Abl kinase activity
by interaction with C-terminal PXXP sequences [21,22], and
through interaction with the c-Abl SH3 domain [24]. No SH3- or
SH2-based mechanism of c-Abl kinase regulation, however, has
been demonstrated for Abi proteins. The LNCaP prostate tumor
cell line contains a mutation in the Abi1 gene that results in
deletion of exon 6 [23]. Exon 6 of Abi1 is within the SH3
domain-binding region [24] pointing to the possibility that this
region might be critical for c-Abl kinase regulation.
We have further investigated regulation of c-Abl kinase by
Abi1 and here report the discovery of a novel allosteric mech-
anism of inhibition of nonmyristoylated c-Abl kinasemediated by
peptides derived from the Abl SH3- and SH2-binding regions of
Abi1.Mutations in either binding site can abrogate the capacity to
inhibit Abl kinase activity. These data are consistent with ob-
served enhanced binding affinity of the consolidated Abi1 ligand
for the dual Abl SH3–SH2 domain over single, i.e. SH3 or SH2,
domain Abi1-derived ligands.We propose that Abi1 plays critical
role in regulating Abl kinase activity in cells.
2. Materials and methods
2.1. Peptides and antibodies
See Fig. 1 for diagrams of peptides. All peptides were synthesized com-
mercially. Anti-pY213 polyclonal antibody was produced to peptide pY213, and
affinity purified using the phosphopeptide-specific column followed by absorption
on the nonphosphopeptide (Y213) column. Polyclonal and monoclonal HA
antibodies were from Covance (Berkeley, CA) and Roche Diagnostic Corporation
(Indianapolis, IN). Antibodies to c-Abl were 8E9 (BDBiosciences, San Jose, CA),K12 (Santa Cruz Biotechnology, Santa Cruz, CA), and pY412 (Biosource
International, Camarillo CA). Antibodies to Crk were from BD Biosciences, San
Jose, CA (mouse monoclonal), Santa Cruz Biotechnology, Santa Cruz, CA (rabbit
polyclonal), and Cell Signaling Technology (phospho-Crk pY221). Polyclonal
antibody, Ab-2, to Abi1 was described previously [25]. Polyclonal antibody, Ab-5,
to Abi1 was made to peptide TPSPPTIGPVADSPTPPP. Monoclonal antibody,
7B6, to Abi1 was produced to recombinant Abi1. The epitope bound by this
antibody is identical to that bound by Mab 4E2 [24]. Antibody to glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was from Imgenex Corporation (San
Diego, CA). GST antibody was from Zymed (San Francisco, CA). GFP antibody
was from Invitrogen (Carlsbad, CA). Generic antibody to phosphotyrosine, PY99,
was from Santa Cruz Biotechnology, Santa Cruz, CA.
2.2. Abl kinase
His-tagged, partially capped, active (nonmyristoylated) c-Abl, E46 through
C-terminus (isoform 1b numbering) was produced in baculovirus from plasmid
(a kind gift of Tony Koleske, Yale University, New Haven, CT) and purified as
described [26] following treatment of insect cells with 30 μM STI-571 (Novartis
Pharma AG, Basel, Switzerland) for 48 hrs prior to cell lysis. The expressed
protein was affinity purified on nickel-nitriloacetic acid agarose, washed to
remove inhibitor, and subsequently purified by ion-exchange chromatography
using a Mono S column (Amersham Biosciences, Piscataway, NJ). GST fusions
of c-Abl SH3 and SH2 domains and the SH2 variant containing an R171K
mutation were obtained from Bruce Mayer (University of Connecticut Health
Center, Farmington, CT). For use in fluorescence quenching experiments the dual
domain SH3–SH2 polypeptide of c-Abl was expressed from plasmid pTXB1
(New England Biolabs, New England, CT) in E. coli BL21 cells. The recombinant
fusion protein was purified through chitin affinitive binding (New England
Biolabs, New England, CT). After DTT cleavage the SH3–SH2 domain was
further purified by SP Sepharose (GEHealthcare, Piscataway, NJ) cation exchange.
2.3. Expression plasmids
Wild type or mutant Abi1 (GenBank Accession No. NM 005470 and
U87166) isoform 2, residue numbering according to [24] were expressed from
plasmids. The mutant Abi1-F213 contains a Y213F replacement. At residues
181–185 the mutant Abi1-Pro replaces the sequence AESEAwith PPSPP, which
results in the loss of a PXXP SH3 binding motif. All Abi1 cDNAs were
subcloned into the pEGFP-N2 plasmid (Clontech, Mountain View, CA)
following removal of GFP-encoding sequences and introduction of an HA tag
at the C-terminus. Untagged wild type isoform 2 of Abi1 was also used for
transfections. In vitro translation of the N-terminus of Abi1 was performed as
described [23]. The C-terminal GFP fusion of the nonmyristoylated c-Abl
(isoform 1a) was obtained from Bruce Mayer.
2.4. Kinase assay
Measurement of kinase activity was essentially as described in [26], using
biotinylated model substrate peptide GGEAIYAAPFKK, [27,28] and 32P-γ-
ATP. SAM2 streptavidin-coated membrane (Promega Corporation, Madison
WI) was used to capture the substrate. Kinase assays were carried out in kinase
buffer (50 mM Tris–HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM
dithiothreitol, 0.01% Brij 35, 100 μM ATP) along with 2nM Abl kinase,
substrate peptides, and Abi1 ligand peptides as indicated. Reactions were carried
out for 5 min. at 30°C. To evaluate c-Abl kinase activity in LNCaP cell lines,
cells were treated with 0.1 mM sodium pervanadate for 10 min. prior to cell
lysis; and the kinase was immunoprecipitated from lysed cells. c-Abl kinase
activity was evaluated by measuring 1) phosphorylation levels of activation loop
tyrosine 412, 2) total tyrosine phosphorylation, and 3) phosphorylation of
endogenous Abl substrate Crk.
2.5. Mass spectrometry
Mass spectrometric analyses of GST-Abi1 peptides were performed using an
Applied Biosystems (Foster City, CA) Voyager DE MALDI mass spectrometer.
Spectra were calibrated against an external or internal standard as needed.
Fig. 1. Identification of c-Abl kinase phosphorylation site. A. Regulatory region of Abi1. Top: Diagram of peptides used in Abl kinase assays. Essential features of
peptides are illustrated relative to Abi1 residues 169 to 217 (GenBank Accession No. U87166). Names of peptides are above lines depicting the specific peptide.
Pro, indicates inclusion of the PXXP motif, PPSPP; Y, indicates tyrosine; pY, indicates phosphotyrosine; F, indicates tyrosine to phenylalanine replacement.
The N-terminus of peptides Pro-pY213, pY213, and F213 peptides used in kinase assays is marked above the sequence with a hooked arrow. Peptides Pro-Y198 and
Pro-F198 span residues 169–203; these peptides exclude pY213 sequence. Peptide EE-Y198 replaces the sequence PPSPP with PESEP resulting in the loss of PXXP
SH3-bindingmotif. Bottom: Diagram depicting in vitro translated polypeptides used initially to characterize tyrosine phosphorylation of theN-terminus of Abi1. AnHA
epitope was introduced at the C-terminus of each polypeptide. Mutations replacing either or both tyrosine residues, Y198, and Y213, in the region of interest are
indicated. Red box represents exon 6 of Abi1 that is lacking in LNCaP cells. B.Mapping of tyrosine phosphorylation of the in vitro translated N-terminus of Abi1 by c-Abl.
Abi1 polypeptides containing the N-terminal half of the protein and indicated mutations of tyrosine residues were subjected to in vitro kinase reactions with c-Abl tyrosine
kinase, followed by separation on SDS-Tricine polyacrylamide gels (7%) and blotting with anti-HA antibody (left) and with the anti-phosphotyrosine antibody, PY-99
(right). WT, wild type polypeptide; F213, polypeptide containing a phenylalanine replacement of tyrosine 213 (Y213F); F198, the polypeptide containing phenylalanine
replacement of tyrosine 198 (Y198F); FF, the polypeptide containing Y213F and Y198F; Lysate, lysate with no Abi1 cDNA.
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LNCaP and Cos7 cells (ATCC, Rockville, MD) were maintained according
to ATCC protocols. Co-transfections of Abi1 with c-Abl in Cos7 cells were
performed with the isoform 1a of c-Abl (nonmyristoylated) and isoform 2 of
Abi1 using Lipofectamine Plus Reagent (Invitrogen, Carlsbad, CA). At 22 h
post-transfection, cells were processed for immunoprecipitation as described
[25] following treatment with 10 µM Gleevec for 30 min. LNCaP cell lines
stably expressing either wild type, clone Abi1(+), HA-tagged Abi1 isoform 2, or
HA-tagged mutants of Abi1 isoform 2 were obtained using G418 selection
(Invitrogen, Carlsbad, CA).
2.7. Immunoprecipitation and Western blotting
c-Abl tyrosine kinase was activated by treatment of LNCaP cells for 10 min
with 0.1 mM sodium pervanadate (freshly prepared from 100 mM activatedsodium orthovanadate and 100 mM H2O2), [29] prior to lysis. Immunopreci-
pitation was performed as described [25]. Western blotting and overlay binding
assay to quantify Abl SH3 domain binding were performed as described [24].
All blots were developed using Supersignal West Pico Chemiluminescence
Substrate (Pierce Biotechnology, Rockford, IL). Images were acquired using a
Kodak GL 440 Imaging System and quantified using Kodak 1D Image Analysis
Software (Version 3.6.4).
2.8. Surface plasmon resonance
Surface plasmon resonance was performed using a Biacore 3000 instrument
(BIAcore Inc., Piscataway, NJ). Biotinylated 14-residue peptides, pY213 or
Y213, were coupled to the surface of a streptavidin-coated (SA) biosensor chip
(BIAcore Inc., Piscataway, NJ). Binding reactions were done in HBS-EP buffer
(10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% (v/v) surfactant
P20). The surface was regenerated before each new injection using 50 mM
Table 1
Y213 Phosphorylation by Mass Spectrometry
Sample [M+H]+
Nonphospho
[M+H]+
Nonphospho/
Met-O‡
[M+H]+
Phospho
[M+H]+
Phospho/
Met-O
WT predicted 2213.1270 2229.1270 2293.1270 2309.1270
WT no c-Abl 2214.76 2229.62 ND ND
WT with c-Abl 2213.27 2229.33 2294.08 2308.85
T15WS no c-Abl 2213.09 2229.13 ND ND
T15WS with c-Abl 2213.69 2229.15 2293.39 2309.38
F213⁎ predicted 2197.1321 2213.1321 Not
applicable
Not
applicable
F213 with c-Abl 2197.27 2213.21 ND ND
Samples were analyzed following trypsin digestion. Predicted and experimental
masses for specific ions containing the indicated tyrosine 213 or phenylalanine
replacement are listed. Sequence for wild type (WT) tryptic peptide:
TLEPVKPPTVPNDpYMTSPAR; the phosphotyrosine 213 is in bold. ⁎F213:
same as WT but with Y213F replacement, in bold: TLEPVKPPTVPNDFMT-
SPAR. T15WS contains residues 144–303 of Abi1 isoform 4 [24] and includes the
same tryptic peptide as WT. ‡Met-O: depicts oxidized methionine (underlined in
tryptic fragments above) that was present in all samples; therefore two (nonpho-
spho-sample) or four (phospho-sample) species of molecules were observed.
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series of binding assays with increasing concentrations of GSTAbl SH2 or GST
Abl SH3–SH2 polypeptides over the same regenerated surface. Derived
sensograms (plots of changes in response unit on the surface as a function of
time) were analyzed using the software BIAeval 3.0. Affinity constants were
estimated by curve fitting using a 1:1 binding model.
2.9. Intrinsic fluorescence measurements
Protein and peptide binding affinities were measured by intrinsic
fluorescence quenching using a Fluorolog-3 fluorimeter (Horiba Jobin Yvon
Inc., Edison, NJ), with excitation at 287 nm and emission detection at 345 nm as
described previously [20]. Fluorescence intensity change was monitored as
SH3–SH2 peptides (2–4 µM in Tris buffer (50 mM Tris, pH 7.4, 150 mMNaCl,
1 mM EDTA)) were titrated by sequential addition of appropriate peptide stock
solution. Data were analyzed using OriginPro 7.5 software (OriginLab Corp.,
Northampton, MA) to fit a modified Stern–Volmer equation [30].
2.10. Statistical Analysis
For Table 2 (evaluation of Km and Vmax), and Fig. 4B (Abl kinase activity in
LNCaP clones) two-tailed paired t-test was used.
3. Results
3.1. c-Abl phosphorylates Y213 of Abi1
Postulating that phosphotyrosines would be components of the
active motif, we searched for tyrosine phosphorylation sites of
Abi1. We determined that candidate tyrosine residues, Y198 and
Y213, are located within the proline-rich region of Abi1 pre-
viously demonstrated to bind the Abl SH3 domain [24]. Using in
vitro-translated polypeptides encoding the N-terminal half of the
protein (Fig. 1A) we determined that Y213 is the preferred site in
the N-terminus of Abi1 of phosphorylation by Abl kinase in vitro
(Fig. 1B). The phosphorylation site at Y213 was confirmed by
mass spectrometry of tryptic peptides following kinase reactions
containing the recombinant Abi1 and active c-Abl (Table 1).
3.2. Identification of the minimal Abl SH3 and SH2 domain
binding sites of Abi1
Using filter overlay assays we have previously localized
binding of the c-Abl SH3 domain to residues 144–260 of Abi1
[24]. This region of Abi1 contains a PXXP SH3 binding motif
located upstreamof tyrosine 213. Deletion of residues 173 through
187 of Abi1 containing the PXXP sequence, 181PPSPP185, almost
completely abolished binding to the c-Abl SH3 domain (Fig. 2A).
The proximity of the Abl SH3 binding site to tyrosine 213 led
us to hypothesize that phosphorylated tyrosine 213 would interact
with the Abl SH2 domain. This putative interaction was analyzed
using a biotinylated 14-residue peptide containing phosphory-
lated tyrosine 213 (pY213) and a GST-Abl SH2 domain fusion
protein (Fig. 2B–D). First, we established that the Abl SH2
domain interacted with the phosphopeptide pY213 but not with
the non-phosphorylated peptide Y213 (Fig. 2B). Then, using
varying concentrations of Abl SH2 we determined that pY213
binds to the SH2 domainwith high affinity (dissociation constant,
KD=3.32×10
−8 M, dissociation rate,Koff=3.76×10
−3 M−1 s−1)
(Fig. 2C). Binding of pY213 with similar high affinity to thedual GST Abl SH3-SH2 domain was observed (dissociation
constant, KD=3.55×10
−8 M; dissociation rate, Koff=2.27×
10−3 M−1 s−1). However, control experiments showed that the
Abl SH2 R171K mutant did not interact with pY213 (Fig. 2D)
consistent with the finding that the R171 mutation renders SH2
domains incapable of interaction with phosphopeptides [31].
3.3. Consolidated Abi1 ligand exhibits enhanced binding
affinity vs. single domain ligands for the dual domain
Abl SH3–SH2 domain
High binding affinity measurements of the GST Abl-SH2
domain to pY213 using surface plasmon resonance (SPR) sug-
gested the possibility of a dimerization effect of theGST fusion tag
[32,33]. Therefore we employed an intrinsic fluorescence
quenching method to determine binding affinities of Abi1
peptides toAbl SH3and SH2domains as previously demonstrated
for optimizedAbl ligands [20]. The binding affinities of Pro-Y198
(containing an SH3 domain-binding sequence), pY213 (contain-
ing an SH2 domain-binding sequence), and Pro-pY213 (contain-
ing the consolidated dual domain SH3–SH2-binding sequence) to
the c-Abl SH3–SH2 dual domain were 2.3±0.4×102 μM, 2.4±
0.4×10 μM, and 9.9±0.4×10−1 μM, respectively. These data,
obtained via intrinsic fluorescence quenching, suggest that both
pY213 and Pro-Y198 are relatively weak binders to their target
domains (Fig. 2E). However, when two ligand binding sequences
are conjoined as in Abi1, the binding of this natural consolidated
ligand, i.e., the peptide Pro-pY213, is of much higher affinity.
3.4. pY213 phosphopeptide inhibits c-Abl kinase activity by a
noncompetitive mechanism
Based on the crystal structure of c-Abl kinase, the SH2
domain-phosphopeptide interaction has the potential to regulate
c-Abl kinase activity [15]. Therefore we performed experiments
to test whether the sequences of Abi1 containing tyrosine 213
Fig. 2. Identification of the minimal binding region of c-Abl SH3 and SH2 domains in the N-terminus of Abi1. A. Binding to c-Abl SH3 domain. Recombinant GST
fusion polypeptides containing the N-terminal terminal region of Abi1/Hsshb3p1 were separated on SDS polyacrylamide gels and transferred onto the nitrocellulose
membrane. The following Abi1 polypeptides were analyzed: N1-187, encoding residues 1–187; N1-172, encoding residues 1–172; N1-253, encoding residues 1–253;
N1-253ΔEx6, encoding residues 1–253 but lacking exon 6 sequences of Abi1 (Macoska et al., 2001); GST, glutathione S-transferase. The bottom panel shows results
when the blots were probed with the anti-GST monoclonal antibody (Anti-GST) to indicate level of protein expression. The top panel was incubated with biotinylated
GST-Abl-SH3 domain (GST-Abl-SH3-B). No binding to biotinylated GST (GST-B) was observed (middle panel). The histogram shows relative binding of
polypeptides, as percent of N1-253 binding, quantified from three independent experiments (n=3,±s.d.). B–D. Binding to c-Abl SH2 domain. Surface plasmon
resonance was used to determine binding between biotinylated 14-residue peptides containing either phosphorylated tyrosine 213 (pY213) or nonphosphorylated
tyrosine 213 (Y213) to GST-tagged Abl SH2 domain. B. Biosensor chips coupled with pY213 or Y213 peptides were injected with the Abl SH2 domain (1 μM).
C. Biosensor chip coupled with pY213 was injected with different concentrations of Abl SH2 domain, as indicated. D. Biosensor chip coupled with pY213 was
injected with 0.5 μM of either the Abl SH2 domain or with the Abl SH2 domain R171K mutant. No binding to the GST protein alone was observed (not shown). RU,
response unit. E. Representative fluorescence titration data using purified Abl dual SH3-SH2 domain. Titration curves for the consolidated dual SH3-SH2 domain
ligand, Pro-pY213, and single domain ligands, Pro-Y198 for Abl SH3 domain, and pY213 for Abl SH2 domain, are indicated.
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Table 2
Kinetic analysis of Abi1 peptides
Peptide Vmax (pmol/min-µg) Fold change (PEP) Km (µM)
PEP 157.79±9.29 1.00 21.19±3.37
F213 163.08±17.90⁎ 1.03 25.79±5.56
pY213 97.51±9.17⁎⁎ 0.62 24.90±5.63
Summary of Vmax andKm (mean±s.d.; n=3) for Abi1 peptides at 1 mM for F213
and pY213. ⁎ p=0.673; ⁎⁎ p=0.001; PEP, substrate peptide. Km differences are
not statistically significant. For description of peptides see Fig. 1A.
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nonmyristoylated, uncapped, c-Abl [26], the model substrate
peptide [27,34] and forms of the 14-residue peptide containing
phosphotyrosine, pY213, or tyrosine to phenylalanine replace-
ment at position 213, F213 (for peptide sequences see Fig. 1A).
Addition of the pY213 phosphopeptide resulted in a 38%
reduction of Vmax but no significant effect on Km of the
substrate peptide, consistent with a noncompetitive mechanism
of inhibition (Fig. 3A–B, and Table 2). No effect on the kinase
activity was observed with the peptide F213.
3.5. Abi1 peptides derived from SH2 and SH3 domain binding
sites regulate c-Abl kinase activity
To determine the role of SH3 domain binding in the regu-
lation of c-Abl kinase activity we performed kinase assays usingFig. 3. Phosphopeptides from Abi1 regulate c-Abl kinase activity in vitro. A. Kinase
peptides at 1 mM. Activity was measured with 5-min kinase assays in the presence o
Burke plots of the data in A. Vertical bars represent s.d. (n=3). See Table 2 for Vmax a
by Abi1 peptides. Concentration of Abi1 peptides is indicated on X axis; substrate
vertical bars represent s.e.m. (n=3). See Fig. 1A for sequence information of peptidas inhibitors various peptides derived from residues 169–217 of
Abi1 (Fig. 1A). As shown in Fig. 3C, peptide pY213 inhibited
kinase activity in a concentration-dependent manner. Peptide
F213, lacking the regulatory tyrosine, did not inhibit kinase
activity. Peptide Pro-pY213, which spans the entire region,
exhibited a more complex effect including slight enhancementactivities (vertical bars represent s.d.; n=3) of c-Abl after addition of indicated
f increasing substrate peptide concentrations. B. Double reciprocal Lineweaver–
nd Km data from these experiments. C and D. Regulation of c-Abl kinase activity
peptide, PEP, was used at 100 µM (see Kinase assay, Materials and methods);
es used here.
743X. Xiong et al. / Biochimica et Biophysica Acta 1783 (2008) 737–747of kinase activity from 0.5 to 1 mM followed by profound
inhibition of activity at higher concentrations. Further experi-
ments demonstrated that Pro-pY213 is capable of up-regulating
or down-regulating c-Abl activity in a concentration-dependent
manner, and that the sequences 181PPSPP185, Y198, and pY213
of Abi1 are critical for this regulation (Fig. 3D).
3.6. Abi1 pY213 and 181PPSPP185 sequences regulate
pervanadate-induced c-Abl tyrosine kinase activity
To determine if Abi1 regulates c-Abl tyrosine kinase activity
in cells we used the LNCaP prostate cancer cell line, which, as a
consequence of a heterozygous deletion of Abi1 exon 6, lacks
the region containing Y213 on one allele. The mutated protein is
not detected in LNCaP cells, and wild type Abi1 is expressed at
a lower than expected level as compared to Abi1 expression in
the primary prostate cell line, PrEC (data not shown). This result
is consistent with haploinsufficiency and suggests the possibi-
lity that c-Abl kinase activity is dysregulated in LNCaP cells.
To test this possibility we first established that the endog-
enous c-Abl tyrosine kinase could be activated by pervanadate
treatment [2] of LNCaP cells (Fig. 4A). Activation of c-Abl
kinase was consistent with phosphorylation of the regulatory
tyrosine pY412 [27] and with total tyrosine phosphorylation of
c-Abl [34]. Therefore in this experimental setting we could
examine whether expression of Abi1 inhibits Abl kinase activa-
tion. We stably transfected LNCaP cells with untagged wild type
isoform 2 of Abi1 (Abi1(+)) or Ha-tagged (Wt.Ha), or with Ha-
tagged Abi1 mutants Y213F (F213.Ha), and 181PPSPP185 to
181AESEA185 (Pro.Ha). As shown in the immunoblots (Fig. 4B
left panel) and the histograms (Fig. 4B, right panel) expres-
sion of intact Abi1 inhibited c-Abl kinase activity, whereas
expression of Abi1 variants carrying a mutated SH2 domain-
binding motif, Y213F, or a mutated SH3 domain-binding motif,
181AESEA185, did not.
Apparently, the introduction of the HA-tag at the C-terminus
of Abi1 reduces the ability of the wild type Abi1 to inhibit Abl
kinase activity (compare Abi1(+) to Wt.Ha cell lines, Fig. 4B).
This would be consistent with a possible negative effect of the
HA tag on the interaction between the SH3 domain at the Abi1
C-terminus and the PRL region of Abl as demonstrated in
numerous studies [21,22].
3.7. Abi1 inhibits nonmyristoylated c-Abl kinase
The data from LNCaP cells suggested that Abi1 is capable of
regulating c-Abl kinase activity. To determine if the observed
mechanism of regulation is pertinent to the nonmyristoylated
kinase as indicated by in vitro kinase data we co-expressed Abi1
and the nonmyristoylated Abl isoform 1a in Cos 7 cells. As
shown in Fig. 4C Abi1 reduced levels of pY412 phosphoryla-
tion of the nonmyristoylated Abl, albeit to a lower extent
than treatment with STI-571. This treatment also inhibited
phosphorylation of Abi1 pY213, and reduced the physical
interaction with Abl (Fig. 4C). A pY213-dependent asso-
ciation of Abi1 with c-Abl was also observed in LNCaP cells
(Fig. 4D).4. Discussion
Based on these results we postulate that phosphorylation of
Y213 of Abi1 by c-Abl kinase is followed by binding of Abi1 to
the Abl SH2 domain with subsequent inhibition of c-Abl kinase
activity. If verified, this would be the first demonstration of
inhibition of c-Abl kinase by a phosphopeptide located in trans
in another protein, in this case, Abi1.
We propose that Abi1 phosphopeptides inhibit c-Abl kinase
through an allosteric mechanism. This mechanism involves
binding of the phosphorylated Y213 to the Abl SH2 domain. An
observed decrease of the Vmax, with no change of the Km is
consistent with a noncompetitive mechanism of inhibition of
kinase activity by the phosphopeptide containing pY213.
However, the effect of pY213 on Abl kinase activity is relatively
weak (decrease of Vmax of about 38% at peptide concentration
of 1 mM). This is in contrast to high binding affinity data
obtained from surface plasmon resonance studies using the GST
tagged Abl SH2 domain. The binding data obtained from
intrinsic fluorescence quenching experiments, obtained with
the untagged protein, or from overlay binding assays [35]
(K. Machida, B.J. Mayer and L. Kotula, unpublished results),
indicate much lower binding affinity of pY213, i.e. in the
micromolar range. These results suggest a strong effect of the
GST tag, most likely due to its dimerization effect, on SH2
binding affinities obtained using SPR as previously suggested
[33]. Our binding data for pY213-SH2, obtained with untagged
protein, is consistent with the relatively weak effect on Abl
kinase activity in vitro.
The in vitro kinase data demonstrated here pertains to the
nonmyristoylated, partially capped, partially activated form of
c-Abl kinase. However, there is no crystal structural information
on the active kinase in the context of the SH3 and SH2 domains.
Recent SAXS [18] studies indicate that the active kinase is
likely to exist in the elongated form. Thus it is possible that
pY213 decreases Abl kinase activity by increasing the rigidity
of the kinase domain through the interactions of the SH2
domain and the N-lobe of the kinase domain, hence the non-
competitive mechanism of inhibition. The noncompetitive
nature of the inhibition is demonstrated by Lineweaver–Burke
plot despite a relatively high concentration of the peptide used
in kinase assay. Supporting the hypothesis that pY213 regulates
c-Abl tyrosine kinase activity through interactions with the c-
Abl SH2 domain, is the fact that pY213 regulates physical
association of Abi1. This is demonstrated here by binding
assays showing interaction of pY213 with the Abl SH2 domain
(Fig. 2) as well as by immunoprecipitation results indicating
that Abi1-pY213 interacts with the active Abl kinase in LNCaP
cells (Fig. 4C and D). pY213 phosphorylation, and conse-
quently the strength of Abi1-Abl kinase interaction, is STI-571-
dependent as indicated by co-transfection experiments. Inter-
estingly, treatment of K562 cells with STI-571 reduced pY213
levels as compared to untreated cells [36] suggesting the
possibility that Abi1 is a substrate of, and functions downstream
of, BCR-Abl.
The lack of a crystal structure of the nonmyristoylated kinase
makes it difficult to interpret the effects of Pro-pY213 peptide
744 X. Xiong et al. / Biochimica et Biophysica Acta 1783 (2008) 737–747on kinase activity. We base our interpretation on the following
facts: 1) Pro-pY213 represents the region from Abi1 that regu-
lates c-Abl kinase activity in vitro. At higher concentrations the
peptide inhibits Abl kinase activity. 2) Mutated or truncated
peptides either inhibit to a lesser extent than Pro-pY213 or do
not inhibit at all. These data permit identification of three critical
elements affecting activity: 181PPSPP185 (representing the core
Abl SH3 domain binding PXXP motif); pY213 (representing
the critical SH2 domain binding phosphotyrosine); and Y198,
which works together with the 181PPSPP185motif as demon-
strated by Pro-Y198 peptide. 3) Multiple conformations of theautoinhibited (inactive) and active Abl kinase are possible based
on recent findings on Abl [18] that include SAXS studies as
well as Src kinase [37]. These studies indicate significant re-
arrangements of the SH3–SH2 dual domain around the catalytic
domain of Src-like family kinases. Therefore, we hypothesize
that different effects of the pY213 and Pro-pY213 and Abl
kinase activity might be a result of different peptide affinities to
transient Abl conformations. For example, the presence of
residual autoinhibitory interactions of the SH3 and SH2 domain
assembly with the catalytic domain of the kinase [16] in the
nonmyristoylated Abl kinase might explain the lack of effect of
Fig. 5. c-Abl kinase regulatory region of the Abi protein family. The region of Abi1 containing the Abl SH3 domain binding site containing the core PXXP consensus,
PPSPP, Y198, and the SH2 domain binding site (underlined, with regulatory phosphotyrosine, pY) is highly conserved during evolution in the Abi protein family.
Critical residues are in bold, non-conserved residues are in red. GenBank Accession numbers for the sequences are the following: for Abi1: Homo sapiens, U87166
and NM_005470; Bos taurus, XP_881074.1; Canis familiaris, XP_858231.1; Mus musculus, Q8CBW3; Xenopus laevis, AAH81178.1; Abi2: Homo sapiens,
NP_005750.3; Mus musculus, AAH79646.1; Gallus gallus, XP_421962.1; Xenopus tropicalis, NP_001007488.1; Danio rerio, XP_685431.1, Drosophila
melanogaster, AAD38382.1. ⁎⁎ denotes insertion of the sequence RAGNTGTLGKSVSNT in Drosophila melanogaster. Consensus is presented in the bottom, where
“x” is K or R, and “z” is S or T, gaps indicate non-conserved residues.
745X. Xiong et al. / Biochimica et Biophysica Acta 1783 (2008) 737–747Pro-pY213 on the kinase activity at lower peptide concentra-
tions. 4) The fact that the binding affinity of the dual domain-
binding Pro-pY213 with Abl SH2 and SH3 domains is much
greater than the sum of the binding affinities of single SH3 and
SH2 ligands suggests that there is a requirement for concurrent
interaction of SH2 and SH3 domains with a consolidated ligand
for regulation of Abl kinase activity.
KI obtained from the kinetic analysis of Abi1 peptides (not
shown) are higher and do not correlate with corresponding KD
obtained from binding assays. One possible explanation may
include the fact that the binding assays were performed with Abl
domain(s) purified from recombinant bacteria, which would beFig. 4. Abi1 inhibits pervanadate-activated Abl kinase activity in LNCaP cells. A. Pe
were treated with 0.1 mM pervanadate for 10 min. prior to cell lysis. Following treatm
on SDS-PAGE gels, and transferred and blotted with indicated antibodies. “pY412”
levels of total tyrosine phosphorylation of c-Abl. “c-Abl” indicates levels of c-Abl kin
was performed with inclusion of phosphatase inhibitors (PPI) as described [25]; “PPI o
“No treatment” indicates untreated cells lysed without phosphatase inhibitors. B. Perv
by immunoprecipitation and examination of phosphorylation levels of the endo
phosphotyrosine pY412 (pY412) and total tyrosine phosphorylation of c-Abl (PY99
K-12, Crk with anti-Crk, Abi1 with 7B6. Expression of the recombinant Abi1 in cell
Abi1 in LNCaP clones expressing HA-tagged Abi1 (Abi1-total), and expression of
immunoprecipitated Abi1 with the polyclonal antibody Ab-5 (Abi1-IP). “GAPDH” in
indicates quantitation of c-Abl kinase activity in the cell lines (n=3; ±s.d.). Crk phosp
and lower in Wt.Ha than in F213.Ha or Pro.Ha (pb0.001) or Mock (pb0.01). Differ
(pb0.05). C. Co-expression of Abi1 or STI-571 treatment inhibits pY412 phosphory
Abi1 with nonmyristoylated c-Abl. Cos 7 cells were co-transfected with HA tagged-A
C-teminus). Cells were treated with STI-571 (10 µM) for 30 min prior to immunopr
evaluated with anti-GFP antibody; levels of pY412 (pY412) and pY213 (pY213) pho
level of co-immunoprecipitated recombinant Abi1was evaluatedwith anti-HA antibod
“input Abi1.”Numbers below blots shows density of specific bands. Note that treatmen
Abl with the recombinant Abi1. D. pY213-dependent interaction of Abi1 with c-Abl
time as indicated. Abi1 was immunoprecipitated with monoclonal antibody 7B6 and th
antibodies: Abi1 with Ab-2 (Abi1-IP), c-Abl with K-12 (c-Abl co-IP). The level of Ab
(pY213); the level of pY213 immunoreactivity with addition of pY213 phosphopept
following immunoprecipitation withK-12 antibody and blottingwith 8E9 is indicated
Numbers below blots shows density of bands indicated by asterisks. There is an app
crossreactivity of this band with pY213 antibody is observed. Note that binding of pY2
the incubation mixture.nonphosphorylated, whereas kinase assays were performed with
partially active, tyrosine phosphorylated kinase obtained from
baculovirus. In this regard, a low level of pY412 and PY-99
immunoreactivity was confirmed in baculovirus-purified kinase
(not shown). Importantly, these types of kinase preparations are
extremely prone to activation due to autophosphorylation
leading to observed differences in basal kinase activity (compare
Fig. 3C and D). Tyrosine phosphorylation of Abl [10] due to
autophosphorylation at or near Abi1 peptide binding regions
may significantly influence their binding affinities.
The Pro-pY213 region of Abi1 represents an important
element that regulates Abl kinase activity in vivo as demonstratedrvanadate treatment enhances c-Abl kinase activity in LNCaP cells. LNCaP cells
ent c-Abl was immunoprecipitated with K12 antibody; proteins were separated
shows level of phosphorylation of the activation loop tyrosine; “pY99” shows
ase in samples. “Pervanadate” indicates cells treated with pervanadate; cell lysis
nly” indicates untreated cells but lysed in the presence of phosphatase inhibitors.
anadate-induced Abl kinase activity in stably transfected cell lines was evaluated
genous Abl substrate Crk (pY-Crk), as well as the c-Abl activation loop
). Proteins were immunopreciptated from indicated stable cell lines: c-Abl with
lysates was evaluated with anti-HA antibody (Abi1-HA Lys); expression of total
total Abi1 in Abi1(+) and LnCAP cell lines was evaluated by blotting of the
dicates lysate input levels used for immunoprecipitation. Histogram on the right
horylation is lower in Abi1(+) than in LnCAP cells or Mock cell line (pb0.001);
ences in pY412 or PY99 phosphorylation among the groups are also significant
lation of nonmyristoylated c-Abl. STI-571 and pY213-dependent interaction of
bi1 and GFP tagged-c-Abl (isoform 1a (nonmyristoylated) with the GFP tag at the
ecipitation as indicated. The level of immunoprecipitated c-Abl (c-Abl-IP) was
sphorylation were evaluated with phosphospecific antibodies, as indicated. The
y (co-IPAbi1). The level of Abi1 expression in transfected cultures is indicated by
t of cells with STI-571 reduces but does not completely abolish the association of
in LNCaP. LNCaP cells were treated with pervanadate for increasing amounts of
e immunoprecipitated proteins were analyzed byWestern blotting using specific
i1 phosphorylation on Y213 in the samples was evaluated by blotting with pY213
ide (10 µM) is indicated (pY213+Pep). The level of c-Abl kinase in cell lysates
by “c-Abl.” “GAPDH” indicates lysate input levels used for immunoprecipitation.
arent crossreactive band above the band with asterisk in the Abi1 IP panel; no
13 antibody to Abi1 can be blocked by inclusion of the phosphopeptide pY213 in
746 X. Xiong et al. / Biochimica et Biophysica Acta 1783 (2008) 737–747in LNCaP cells. Abi1 Y213F or 181AESEA185 mutants did not
inhibit Abl kinase activation, which indicates that concurrent
binding of Abi1 to both SH3 and SH2 domain of Abl is critical for
regulation. This is consistent with in vitro binding data
demonstrating significant enhancement of the binding affinity
of the consolidated Abi1 ligand over single-site ligands. It is
possible that the 181AESEA185 mutant, despite having a higher
affinity binding site for Abl, is incapable of Abl inhibition in
LNCaP cells because of lower expression of total Abi1 in
comparison to the clone that expresses wild type Abi1-Ha.
LNCaP cells express both isoforms of Abl i.e. myristoylated and
nonmyristoylated as determined by mRNA analysis (data not
shown). Thus, the effects of the recombinant Abi1 on both
isoforms of kinase cannot be excluded in these cells.
The hypothesis that Abi1 acts on the nonmyristoylated
isoform of Abl is suggested by inhibition of the kinase in co-
transfection experiments in Cos7 cells. Apparently, the non-
myristoylated kinase is constitutively active upon transfection
into cells, while Abl kinase must be activated with pervanadate
in LNCaP cells in order to demonstrate regulation by Abi1. As
pervanadate is considered a general tyrosine phosphatase
inhibitor, the action of Abi1 on Abl may be through an allosteric
effect, as we postulate, or through a “shielding” effect on the
catalytic domain by Abi1 SH3 domain interacting with the
proline-rich region of c-Abl [22]. Thus, steric hindrance caused
by tagging of Abi1 at the C-terminal may decrease its inhibitory
effect on Abl kinase as demonstrated here. We cannot exclude
the possibility that Abi1 is also a competitive inhibitor in vivo in
addition to its allosteric inhibition. Importantly, Abi1 must be
phosphorylated at pY213, presumably by Abl, for the proposed
regulation to occur. Consequently, in intact cells, Abi1 is both a
candidate substrate and the candidate regulator of Abl kinase
activity.
The proposed mechanism of regulation of c-Abl by Abi1
includes the possibility that Abi1 plays a role in the initial
activation of c-Abl as proposed [38]. This hypothesis would
most likely apply to the myristoylated, autoinhibited kinase.
Structural studies of c-Abl [15,16] indicate that the phosphotyr-
osine binding site is partially occluded in the crystal structure of
the myristoylated c-Abl fragment containing the SH3–SH2-
catalytic domain assembly. Thus, Pro-pY213 could potentially
activate the myristoylated kinase through the SH2 domain
interaction as proposed [15,16]. It is also possible that Abi1 may
downregulate c-Abl that has been activated by phosphopeptides
[15]. This might occur, for example, by competing off the
activating phosphopeptide by Abi1-pY213.
Conservation of the regulatory sequences suggests that other
members of Abi/Hssh3bp1 family of proteins also regulate Abl.
The region containing the regulatory tyrosine 213 is highly
conserved between Abi1 and Abi2 from Xenopus through
human, and is present inDrosophilaAbi (Fig. 5). The conserved
sequences also include the PXXP motif, 181PPSPP185, which
binds to the c-Abl SH3 domain, and tyrosine 198. All isoforms
of Abi1 [22,24,39], or Abi2 [21] contain the regulatory sequence
indicating the conservation of c-Abl regulation in all Abi iso-
forms. The conserved region of Abi1 apparently plays a role in
the regulation of c-Abl kinase activity in cells; here we addressedthe role of the regulatory sequences in the context of Abi1
isoform 2. The fact that multiple isoforms are expressed from the
Abi1/Hssh3bp1 gene [24] suggests the possibility of differential
effects on Abl kinase activity as well as multiple downstream
effects on actin cytoskeleton and Wave complex regulation
[40,41].
In summary, we identified a candidate molecular mechanism
of regulation of nonmyristoylated Abl kinase. Nonmyristoy-
lated, mutated forms of Abl, such as BCR-Abl, are implicated in
chronic myelogenous leukemia and in some forms of acute
lymphocytic leukemia [3,4]. Although the use of STI-571 has
brought great promise for the treatment of these diseases, some
patients have become resistant to the drug following long-term
treatment. STI-571-resistance mutations are found in Abl SH3
and SH2 domains [42] suggesting the possibility that in these
cases BCR-Abl escapes possible residual regulation by other
interactions including that with Abi1. The studies described
here may improve our understanding of the mechanisms of Abl
regulation, and may directly impact studies of BCR-Abl.
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